Melioidosis Clinical Trial
— ATOMOfficial title:
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.
Status | Recruiting |
Enrollment | 750 |
Est. completion date | September 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 15 Years and older |
Eligibility |
Inclusion criteria (all criteria must be satisfied) A. Community acquired sepsis, and melioidosis is suspected: Suspected melioidosis (12): all of the following are defined as 'clinically probable' melioidosis - A history of frequent contact with soil or surface water in the endemic area - At least one of the following risk factors: diabetes mellitus, chronic renal failure or renal calculi, thalassaemia, aplastic anaemia or steroid abuse - An illness compatible with melioidosis, including the presence of sepsis, acute pneumonia, acute pyelonephritis, septic arthritis, parotid disease or skin or soft tissue infection, or - An evidence of intra-abdominal suppuration (hepatic or splenic abscesses) regardless of risk factors or exposure history Sepsis: defined as patients who have Systemic Inflammatory Response Syndrome (SIRS) - two or more of the following, clinically ascribed to infection: - Fever: temperature >38°C or <36°C - Tachycardia: heart rate >90 beats/min - Tachypnoea: 1. Respiratory rate >20 breaths/minute; or 2. PaCO2 <32 mmHg; or 3. Mechanical ventilation - White cell count >12,000 cells/mL or <4,000 cells/mL or >10% band forms B. Age > 14 years. C. Need hospitalisation and intravenous antibiotic administration. D. Willingness to participate in the study and written, informed consent obtained from the patient. Exclusion Criteria (any one of the following): A. Pregnant or lactating women. B. Known hypersensitivity to meropenem or ceftazidime. C. Previous isolate with known resistance to ceftazidime or meropenem. D. Patients not expected to remain in hospital for treatment. E. Patients with community-acquired sepsis with cultures positive for other organisms. F. Patients treated with antibiotics active against B. pseudomallei (including ceftazidime, amoxicillin-clavulanate, meropenem) for this episode for greater than 24 hours. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Thailand | Sappasithiprasong Hospital | Ubonratchathani | Ubon |
Thailand | Udon Thani General Hospital | Udon Thani |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | Mahidol University, Wellcome Trust |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | All cause mortality | In hospital | No | |
Secondary | All cause mortality in patients culture positive for melioidosis | In hospital | No | |
Secondary | Switch of antimicrobial therapy | In hospital | Yes | |
Secondary | Adverse drug reactions | 1 month | Yes | |
Secondary | Fever clearance time (time to body temperature of less than 37.5°C for at least 48 hours) | In hospital | No | |
Secondary | Length of hospital stay | months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04299412 -
Diagnostic Accuracy of the DPP II Assay
|
||
Recruiting |
NCT06089668 -
An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
|
||
Completed |
NCT03528265 -
Adapting LFI for Melioidosis
|
||
Completed |
NCT05105035 -
Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
|
Phase 2 | |
Completed |
NCT01766830 -
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
|
N/A | |
Recruiting |
NCT03048513 -
Clinical Presentation of Melioidosis in Head and Neck Region
|
N/A | |
Completed |
NCT02668406 -
Study to Obtain Blood and Voided Urine Samples to Improve the Diagnosis of Melioidosis
|
||
Completed |
NCT01420341 -
Co-trimoxazole as Maintenance Therapy for Melioidosis
|
Phase 4 | |
Completed |
NCT02089152 -
A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand
|
N/A |